448 related articles for article (PubMed ID: 31483163)
1. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
2. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response.
Lu J; Wei S; Lou J; Yin S; Zhou L; Zhang W; Zheng S
Med Sci Monit; 2020 Jul; 26():e925733. PubMed ID: 32706768
[TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
5. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
6. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
7. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
8. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
9. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
[TBL] [Abstract][Full Text] [Related]
10. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
12. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
14. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma.
Yang C; Wu Q; Huang K; Wang X; Yu T; Liao X; Huang J; Zhu G; Gong Y; Han C; Su H; Qin W; Peng T
Front Oncol; 2019; 9():511. PubMed ID: 31275849
[TBL] [Abstract][Full Text] [Related]
16. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
18. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
19. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
[TBL] [Abstract][Full Text] [Related]
20. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]